Sequoia China co-leads $37.5m Series B for biotherapeutics firm HiFiBiO

Sequoia China co-leads $37.5m Series B for biotherapeutics firm HiFiBiO

Photo: Bloomberg

HiFiBiO Therapeutics, an emerging multinational biotherapeutics company that seeks to combat diseases by mobilizing the human immune system, has raised $37.5 million in a Series B financing co-led by Sequoia China and LYFE Capital.

Existing Series A investors VI Ventures and Nest.Bio Ventures, as well as new investors Legend Star Capital and Proxima Ventures, also backed the funding round of the US-based startup that also has offices in France and China.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter